Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E M Griffiths

Showing results (261-270 of 337) with videos related to

Pageof 34
Sort By:
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Rheumatology and Therapy|September 27, 2021
Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online SurveyLaura C Coates, Valderilio F Azevedo, Joseph C Cappelleri, et al.
The Journal of Investigative Dermatology|February 22, 2023
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with BiologicsAli Al-Janabi, Steve Eyre, Amy C Foulkes, et al.
American Journal of Clinical Dermatology|March 18, 2024
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, CanadaAnastasiya Muntyanu, Raymond Milan, Mohammed Kaouache, et al.
The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.
The Journal of Investigative Dermatology|August 28, 2009
Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging studyC Elise Kleyn, Shane McKie, Andrew R Ross, et al.
The British Journal of Dermatology|January 25, 2023
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort studyAli Al-Janabi, Amelle Ra, Zoe Littlewood, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The Journal of Investigative Dermatology|December 31, 2005
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasisHelen S Young, Angela M Summers, Ian R Read, et al.
Pageof 34

Showing results (261-270 of 337) with videos related to

Sort By:
Pageof 34
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Rheumatology and Therapy|September 27, 2021
Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online SurveyLaura C Coates, Valderilio F Azevedo, Joseph C Cappelleri, et al.
The Journal of Investigative Dermatology|February 22, 2023
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with BiologicsAli Al-Janabi, Steve Eyre, Amy C Foulkes, et al.
American Journal of Clinical Dermatology|March 18, 2024
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, CanadaAnastasiya Muntyanu, Raymond Milan, Mohammed Kaouache, et al.
The New England Journal of Medicine|January 15, 2010
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasisChristopher E M Griffiths, Bruce E Strober, Peter van de Kerkhof, et al.
The Journal of Investigative Dermatology|August 28, 2009
Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging studyC Elise Kleyn, Shane McKie, Andrew R Ross, et al.
The British Journal of Dermatology|January 25, 2023
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort studyAli Al-Janabi, Amelle Ra, Zoe Littlewood, et al.
The British Journal of Dermatology|July 17, 2025
Mendelian randomization identifies OX40 as a potential mediator of the effects of cigarette smoking in palmoplantar pustulosisAlice Smail, Nick Dand, Xinyue Liu, et al.
The Journal of Investigative Dermatology|December 31, 2005
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasisHelen S Young, Angela M Summers, Ian R Read, et al.
Pageof 34